Title:
治療用第VIII因子抗体
Document Type and Number:
Japanese Patent JP2013542188
Kind Code:
A
Abstract:
The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A.
Inventors:
Henrik Ustago
Eda Hilden
Heidi Lindgreen Holmberg
Casper Lumbers
Yes Toan Krausen
Eda Hilden
Heidi Lindgreen Holmberg
Casper Lumbers
Yes Toan Krausen
Application Number:
JP2013529613A
Publication Date:
November 21, 2013
Filing Date:
September 15, 2011
Export Citation:
Assignee:
Novo Nordisk Ar/S
International Classes:
C07K16/36; A61K39/395; A61P7/04; C12N15/02; C12P21/02; C12P21/08
Domestic Patent References:
| JP2009274958A | 2009-11-26 |
Other References:
JPN6007005521; 武山雅博ら: '第ＶＩＩＩ因子活性増強作用を有する第ＶＩＩＩ因子（ＦＶＩＩＩ）Ａ１／Ａ３ドメイン認識抗体' 第６８回日本血液学会・第４８回日本臨床血液学会合同総会プログラム・抄録集 , 20060930, 第２６９頁（ＰＳ-１-７６）
JPN6015039524; Ｔｈｒｏｍｂｏｓｉｓ ａｎｄ Ｈａｅｍｏｓｔａｓｉｓ Ｖ． １０３， Ｎ． １, 201001, ｐｐ． ９４-１０２
JPN6015039524; Ｔｈｒｏｍｂｏｓｉｓ ａｎｄ Ｈａｅｍｏｓｔａｓｉｓ Ｖ． １０３， Ｎ． １, 201001, ｐｐ． ９４-１０２
Attorney, Agent or Firm:
Yasuhiko Murayama
Masatake Shiga
Takashi Watanabe
Shinya Mitsuhiro
Masatake Shiga
Takashi Watanabe
Shinya Mitsuhiro